

## Corticosteroids In the Treatment of Acute Asthma

Marzouq Rasheed Alanazi<sup>1</sup>, Raad Saeed Alotaibi<sup>2</sup>, Mojahed Ahmed Shuker<sup>3</sup>, Jaber Ahmed Mahzari<sup>4</sup>, Mohammed Saad Alqahtani<sup>5</sup> and Faisal Mohammed Alaklabi<sup>6</sup>

### Abstract

*While most of patients can be released from intense consideration offices, like the crisis division (ED), intense asthma is a pervasive reason for introductions. Backslides requiring further clinical consideration are normal. Earlier examination has shown that the utilization of high dosages of breathed in corticosteroids (ICS) lessens the occurrence of emergency clinic affirmation in intense settings. Clinical practice rules support foundational corticosteroids for the treatment of intense asthma intensification on account of information showing improved results and less hospitalizations following emergency room conveyance. Oral/fundamental corticosteroids were by and large used to treat asthma, and they were utilized more frequently in patients with serious asthma than in those with less extreme side effects. By and large, more limited lengths of oral or foundational corticosteroid organization were more normal than longer ones. Indeed, even at exceptionally unassuming doses, delayed and intermittent transient oral/fundamental corticosteroid use was connected to a higher gamble of both intense and constant secondary effects when contrasted with no utilization. Expanded costs and the usage of medical care assets were likewise connected to higher openness to oral and fundamental corticosteroids.*

**Keywords:** Acute Asthma, Inhaled Corticosteroids, Systemic Corticosteroids, Intramuscular Corticosteroids

### INTRODUCTION

Around 300 million people overall experience the ill effects of asthma, which is the reason for one out of each and every 250 fatalities around the world. Every year, almost 12 million people in the US experience an acute asthma exacerbation; 25% of these individuals need to be hospitalized. One needs to distinguish between inadequate asthma control and acute asthma. Intense asthmatic patients will encounter deteriorating hacking, wheezing, chest snugness, or potentially windedness. On the other hand, inadequate management of asthma frequently manifests as a daily fluctuation in airflow, a feature that is normally absent during an acute exacerbation (Ferguson et al., 2017).

Severe asthma flare-ups represent a substantial financial, personal, and public health burden and are frequently the reason for ED visits. Every year, about 500,000 people are admitted to hospitals and 1.8 million ED visits in the US due to acute asthma. Controlled oxygen, short-acting beta-agonists (SABA) like salbutamol managed by means of a metered-portion inhaler (MDI) or nebulizer, nebulized ipratropium, and foundational corticosteroids (SCS) like oral prednisolone or intravenous hydrocortisone are standard medicines for intense asthma in the crisis division (ED). At the point when grown-ups and kids experience intense asthma assaults, oral and parenteral steroids can decrease the requirement for hospitalization in the result, especially in instances of serious intensifications. Inhaled corticosteroids at high doses (ICS) are an additional therapeutic option (Kearns et al., 2020).

The understanding of which treatments work best for managing acute asthma has improved over the last few decades. The mainstays of treatment for acute asthma remain to be bronchodilators and systemic corticosteroids. Asthma management's long-term objectives are to limit the chance of an asthma exacerbation,

---

<sup>1</sup> Respiratory Therapist, Alymammah hospital, Al Riyadh , Saudi Arabia

<sup>2</sup> Respiratory Therapist, King Abdulaziz Air Base - Armed Forces Hospital, Al Dhahran, Saudi Arabia

<sup>3</sup> Respiratory Therapist, King Abdulaziz Air Base - Armed Forces Hospital, Al Dhahran, Saudi Arabia

<sup>4</sup> Respiratory Therapist, King Abdulaziz Air Base - Armed Forces Hospital, Al Dhahran, Saudi Arabia

<sup>5</sup> Respiratory Therapist, King Abdulaziz Air Base - Armed Forces Hospital, Al Dhahran, Saudi Arabia

<sup>6</sup> Anesthesia Technician, King Abdulaziz Air Base - Armed Forces Hospital, Al Dhahran, Saudi Arabia

maintain regular activity, and effectively control symptoms. But even with the best management, 10% of asthmatic patients will have a severe flare-up that calls for oral corticosteroids (Maselli & Peters, 2018).

When systemic corticosteroids (SCS) were first made accessible in 1956, asthma symptoms and exacerbations could be effectively managed. However, because of their broad use, it was before long understood that drawn out SCS use is connected to serious unfriendly impacts (AEs). Presented in 1972 as an upkeep treatment for individuals with asthma, breathed in corticosteroids (ICS) have a lower chance of unfriendly occasions (AEs) however are similarly powerful as SCS for most of patients. In any case, for the accompanying forty years, SCS — regularly directed as oral corticosteroids, or OCS — and once in a while controlled as injectable corticosteroids — kept on being the foundation treatment for serious asthma assaults (Bengtson et al., 2017).

Since clinical advantages may not appear for somewhere around 6 to 12 hours, all patients with intense extreme asthma ought to get oral or parenteral corticosteroids quickly (Agnihotri & Saltoun, 2019).

Systemic corticosteroids (SCS) have been widely used in the treatment of asthma since their effectiveness was first noted in the 1950s. SCS are often recommended as short- and long-term treatments for chronic ocular disorders. When it comes to treating acute asthma symptoms, especially exacerbations, short-course SCS are a highly efficient and quick treatment option. It is often advised that patients receive SCS within one hour of presenting symptoms, as this is regarded as standard of care for treating acute asthma exacerbations (Bourdin et al., 2019).

### **Significance of Study**

When treating patients with acute asthma exacerbations in the ED and after they are discharged, corticosteroids are crucial. 1949 saw the investigation of the use of cortisone as an arthritis treatment by Hench et al., shortly after the structure of adrenal steroid hormones was discovered. The next year, that work was awarded the Nobel Prize because to its extraordinary impact. Additionally, it initiated a number of corticosteroid trials for different inflammatory disorders. In 1956, corticosteroids were used for the first time to treat acute asthma exacerbation. (Alangari, 2018).

With the advancement of corticosteroids with diminished mineralocorticoid movement (prednisone) and later corticosteroids with no mineralocorticoid action (dexamethasone), corticosteroids turned out to be more engaging as asthma medicines. Subsequent studies were published detailing the effectiveness of IV methylprednisolone, oral prednisone and prednisolone, and inhaled corticosteroids (ICS) such fluticasone, budesonide, and triamcinolone in the treatment of asthma (Alangari, 2018).

### **Objectives**

To estimate the efficacy of Inhaled corticosteroid in the treatment of acute asthma.

To examine the effectiveness and safety of systemic corticosteroids.

To examine the effectiveness and safety of intramuscular (IM) corticosteroids.

### **Literature Review**

An aggravation of the aviation routes prompting the lungs causes choking, which causes wheezing, coughing, and trouble breathing during an asthma episode. People who have asthma episodes frequently visit emergency rooms. Strong anti-inflammatory drugs called corticosteroids are the mainstay of treatment for asthma flare-ups and have been demonstrated to be beneficial in enhancing lung function and lowering hospital admission rates for asthmatic patients. Corticosteroids are frequently given to patients upon discharge in order to lower the likelihood that they would visit the emergency room again owing to increasing asthma symptoms. Corticosteroids can be taken as pills to take home or as a single injection under the skin into the muscle (a process known as "intramuscular" injection). At the moment, it is unknown if corticosteroid regimen is more beneficial at improving patient outcomes after being discharged from the emergency room (Kirkland et al., 2018).

Asthma is effectively treated with corticosteroids because they lessen airway inflammation. Systemic corticosteroids are recommended during an exacerbation, even though asthma corticosteroids are commonly administered by inhalation for stable condition. For all cases of asthma exacerbations even the mildest, systemic corticosteroids are advised. Intravenous or intramuscular routes do not offer a significant advantage over the oral route, despite much discussion over the mode of delivery. If the patient is able to take oral medication and improper intestine absorption is not an issue, then the oral route is recommended. Better results have been linked to early systemic corticosteroid therapy. While documented asthma action plans could include increasing the number of inhaled corticosteroids when an exacerbation occurs. According to previous research, giving inhaled corticosteroids to patients who are first presenting in the emergency room with an asthma exacerbation has advantages. Early use of high-dose inhaled corticosteroids may be a better option than oral corticosteroids for milder exacerbations. (Maselli & Peters, 2018).

As of now, breathed in corticosteroid (ICS) is the fundamental treatment for tireless asthma, with extra regulator treatments — generally lengthy acting  $\beta$ 2-agonists (LABAs) and leukotriene receptor bad guys — filling in as strengthening measures to bring down ICS doses, oversee asthma side effects, and lower the gamble of worsening for asthmatic patients. Patients with asthma who are not constrained by medium-to high-measurements breathed in corticosteroids (ICS) and regulator drugs are encouraged to get add-on medicines, which were typically lengthy acting muscarinic bad guys or low-dose oral corticosteroid (OCS) preceding the presentation of designated biologics (Reddel et al., 2022).

The gamble of creating OCS-related entanglements, like contaminations, diabetes, osteoporosis, and mental issues, was higher for patients with long haul OCS openness contrasted and control gatherings, in any event, for those getting measurements under 5 mg/d, as per a new efficient writing survey that assessed the drawn-out utilization of oral corticosteroid (OCS) for patients with asthma. In any case, these outcomes depended on few distributions and were confined to grown-up patients with extreme asthma who had been involving OCS for quite a while (Bleecker et al., 2020).

Based on its longer biologic half-life and better palatability, researchers have evaluated dexamethasone as an alternative to prednisone and comparable oral preparations, notwithstanding the former recommendation. Systematic studies of several short trials and two bigger trials have not revealed any difference in ER visits whether dexamethasone is administered orally or by intramuscular injection when compared to prednisone. Research on oral conveyance has shown that dexamethasone causes less regurgitating than prednisone, both in the trauma center and when required orally a subsequent time, generally 24 to 48 hours after the fact. Contrasting examinations assessing a solitary measurement of dexamethasone to various dosages of prednisone, the outcomes showed comparable recuperation at follow-up, however there was likewise a few proofs of deteriorated side effects and a more prominent requirement for additional corticosteroids (Abaya et al., 2018).

## **Inhaled Corticosteroid**

The last 30 years have seen a sharp drop in the mortality rates from asthma, mostly as a result of better diagnosis and treatment, especially in the 1990s when inhaled corticosteroids (ICSs) became more widely used. Because the variables linked to these outcomes are not well known, the effect of ICS on other long-term outcomes, like the loss in lung function, is less clear. Since ICS treatment has been shown to improve all asthma symptoms and lower asthma mortality during the past 10 years, it has been advised for all patients whose symptoms need taking a relief twice a week or more. ICSs are currently prompted as a treatment choice for all patients because of a developing acknowledgment that patients who were recently remembered to have gentle asthma truly have higher dreariness than recently suspected. One more generally late expansion to treatment suggestions is the utilization of ICS/quick beginning  $\beta$ 2-agonist as a reliever drug for all asthma patients, instead of SABA alone (O'Byrne et al., 2019).

The first-line anti-inflammatory treatment for chronic asthma of all severity levels is currently inhaled corticosteroids (ICSs). By lowering airway inflammation, they affect hyperresponsiveness as a result. ICSs lessen the severity of symptoms and enhance lung function in this way. Additionally, they work well to stop or lessen the frequency of asthma flare-ups. The capacity of ICSs to specifically target every cell implicated in asthmatic

inflammation is linked to their anti-inflammatory effect. At the location of action in the airways, ICSs initiate their anti-inflammatory action. Nevertheless, when ICS concentrations in the airways above specific thresholds, they do not synchronize with downstream systemic medication concentrations that dictate the emergence of harmful systemic consequences (Matera et al., 2019).

The mainstay of treatment for children with asthma who are five years of age or younger is inhaled therapy; the type of device used depends on the child's age and capacity. The Global Initiative for Asthma recommends a pressurized metered-dose inhaler + spacer as the best medication delivery method for young children with asthma. For those under three years old, a facemask is required; for those between the ages of four and five, one should not use one (Murphy et al., 2020).

The ICS portion reaction relationship for foundational antagonistic impacts, like the gamble of adrenal concealment, waterfalls, breaks, and diabetes, varies from that for adequacy results. There is an ever-evolving expansion in the gamble of adrenal concealment, waterfalls, breaks, and diabetes with expanding ICS portion, without a level essentially as occurs with viability results, as per various orderly surveys and meta-examinations of randomized controlled preliminaries (Beasley et al., 2019).

### **Side Effects**

The most common family concern regarding inhaled corticosteroids (ICSs) is that they may have a negative impact on growth velocity, which could result in poor adherence. Various significant development related arbiters are known to be upset by glucocorticoids; these incorporate collagen combination, adrenal androgen creation, development chemical discharge and action, insulin-like development factor 1 bioactivity, osteoblast action, and the speed increase of chondrocyte apoptosis. Also, glucocorticoids have been displayed to downregulate the statement of development chemical receptors in the liver and development plate (Heffler et al., 2018).

### **Systemic Corticosteroids**

By forestalling the union of solid supportive of incendiary arbiters and bringing down the chemotaxis of provocative cells to the lungs, fundamental corticosteroids (SCS) meaningfully affect asthmatic aviation routes. Critical over-endorsing of SCS has been recorded in grown-ups and youngsters with asthma, possibly because to their effectiveness, relative price, or the belief that short courses are safe (Bourdin et al., 2020).

In an emergency for patients who are at danger of exacerbations, SCS are recommended as part of asthma self-management strategies; if this is not done appropriately, it could result in improper medication use, which puts patients at risk of negative side effects. In the in the meantime, overprescription of SCS might be an indication of deficient administration of asthma, which can be brought about by various things, for example, ill-advised inhaler use and unfortunate adherence to breathed in treatment (breathed in corticosteroids, or ICS). Besides, people with asthma might utilize SCS for asthma as well as for usually co-happening conditions, for example, rhinosinusitis regardless of nasal polyps, atopic dermatitis, urticaria, and conjunctivitis that manifest as sicknesses that eruption. SCS are frequently recommended, even in cases where there is no data to support their usage, for a range of ailments (Dvorin & Ebell, 2020).

Long-term SCS use has a number of systemic consequences that have been thoroughly investigated and documented. Type II diabetes, corpulence, adrenal concealment, cardiovascular infections, osteoporosis, and osteopenia are the most predominant critical comorbidities connected with SCS. Moreover, mental side effects like sleep deprivation, madness, uneasiness or forceful way of behaving, contaminations, dyslipidemia, hypertension, waterfalls, glaucoma, wounds, changes by all accounts, skin striae, and changes in hunger have all been connected to the utilization of SCS (Price et al., 2018).

### **Side Effects**

Both longer-term and short-term intermittent usage of systemic corticosteroids (SCS) are associated with hazards. According to a recent study, 93% of patients with severe asthma had at least one comorbidity from their exposure to SCS. This covers mortality and, above all, morbidity. Compared to non-SCS use, regular SCS use is linked to higher all-cause mortality. According to a nationwide asthma cohort study conducted in Sweden,

those with asthma who regularly used SCS were 1.34 times more likely to die than those who did not. Even with brief periods of treatment, the reductions in asthma symptoms observed with SCS must be weighed against the potential negative effects of this medication (Ekström et al., 2019).

The utilization of OCS/SCS, both short-and long haul, has been connected to a raised gamble of intense and persistent issues, and this hazard ascends with more openness, as indicated by recognized research. The burden of comorbidities brought on by both prolonged and recurrent short-term OCS/SCS use increases the burden of asthma and raises the risk of hospitalization and ER visits, as well as the need for medical resources. We discovered reports of 43% higher total healthcare costs and 58% higher non-asthma-related costs for patients undergoing long-term OCS therapy compared with nonusers (Bleeker et al., 2020).

### **Intramuscular (IM) Corticosteroids**

These investigations demonstrated that intramuscular repository corticosteroids were just as beneficial as oral corticosteroids. It has been shown that adherence is the biggest problem for asthma patients going off oral medications. Owing to the large number of medications and frequent dosage adjustments, oral steroid dosage reduction has been proven to be challenging (Thomas EJ, 2021).

A safe approach was established by a single injection of methylprednisolone given to patients with COPD and asthma without any adverse effects being noticed for more than a month. Clinical management may take into consideration the administration of a single intramuscular dosage of methylprednisolone in an attempt to prevent confusion and the under- or overuse of steroids (Abubaker, J, 2019).

Using techniques to enhance asthma control may also be beneficial. These include: 1) using combination medications only when necessary for mild cases of asthma; 2) reducing risk factors; 3) enhancing adherence and inhaler technique; 4) raising the dose of inhaled corticosteroids (ICS) during exacerbations; 5) starting add-on therapies earlier; 6) utilizing biologics in reasonable patients; and 7) growing new treatments to more readily control the illness and forestall intense asthma side effects/intensifications that will require SCS. Most importantly, the clinical local area should be broadly instructed. To include our patients in their consideration, it is likewise fundamental that they are educated about the consolidated unfriendly impacts regarding SCS and high-portion ICS. By taking these steps, you could restrict the use of SCS to patients who are eligible (Price et al., 2020).

### **CONCLUSION**

Asthma is a far reaching constant respiratory sickness, and intense asthma eruptions are one of the primary reasons individuals visit the trauma center (ED) and are confessed to the clinic, particularly in kids. The most eminent neurotic quality of asthma is irritation of the bronchial aviation routes. For a long time, the foundation of asthma treatment has been breathed in corticosteroids (ICS), because of their calming properties. Intense asthma eruptions are additionally treated with foundational and ICS meds. While getting moderate serious intense asthma, foundational corticosteroids ought to be begun when the patient shows up at the crisis division, as per various overall norms for asthma treatment.

### **REFERENCES**

- Ferguson, J. E., Patel, S. S., & Lockey, R. F. (2017). Acute asthma, prognosis, and treatment. *Journal of Allergy and Clinical Immunology*, 139(2), 438–447. <https://doi.org/10.1016/j.jaci.2016.06.054>
- Kearns, N., Majiers, I., Harper, J., Beasley, R., & Weatherall, M. (2020). Inhaled corticosteroids in acute asthma: A systemic review and meta-analysis. *The Journal of Allergy and Clinical Immunology: In Practice*, 8(2). <https://doi.org/10.1016/j.jaip.2019.08.051>
- Abaya, R., Jones, L., & Zorc, J. J. (2018). Dexamethasone compared to prednisone for the treatment of children with acute asthma exacerbations. *Pediatric Emergency Care*, 34(1), 53–58. <https://doi.org/10.1097/pec.0000000000001371>
- Maselli, D. J., & Peters, J. I. (2018). Medication regimens for managing acute asthma. *Respiratory Care*, 63(6), 783–796. <https://doi.org/10.4187/respcare.05953>
- Agnihotri, N. T., & Saltoun, C. (2019). Acute severe asthma (status asthmaticus). *Allergy and Asthma Proceedings*, 40(6), 406–409. <https://doi.org/10.2500/aap.2019.40.4258>

- Kirkland, S. W., Cross, E., Campbell, S., Villa-Roel, C., & Rowe, B. H. (2018). Intramuscular versus oral corticosteroids to reduce relapses following discharge from the Emergency Department for Acute Asthma. *Cochrane Database of Systematic Reviews*, 2018(6). <https://doi.org/10.1002/14651858.cd012629.pub2>
- Bengtson, L. G., Yu, Y., Wang, W., Cao, F., Hulbert, E. M., Wolbeck, R., Elliott, C. A., & Buikema, A. R. (2017). Inhaled corticosteroid-containing treatment escalation and outcomes for patients with asthma in a U.S. Health Care Organization. *Journal of Managed Care & Specialty Pharmacy*, 23(11), 1149–1159. <https://doi.org/10.18553/jmcp.2017.23.11.1149>
- Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., Fleming, L. J., Inoue, H., Ko, F. W., Krishnan, J. A., Levy, M. L., Lin, J., Mortimer, K., Pitrez, P. M., Sheikh, A., ... Boulet, L.-P. (2022). Global initiative for asthma strategy 2021: Executive summary and rationale for key changes. *American Journal of Respiratory and Critical Care Medicine*, 205(1), 17–35. <https://doi.org/10.1164/rccm.202109-2205pp>
- Bleeker, E. R., Menzies-Gow, A. N., Price, D. B., Bourdin, A., Sweet, S., Martin, A. L., Alacqua, M., & Tran, T. N. (2020). Systematic literature review of systemic corticosteroid use for asthma management. *American Journal of Respiratory and Critical Care Medicine*, 201(3), 276–293. <https://doi.org/10.1164/rccm.201904-0903so>
- Bourdin, A., Bjermer, L., Brightling, C., Brusselle, G. G., Chanez, P., Chung, K. F., Custovic, A., Diamant, Z., Diver, S., Djukanovic, R., Hamerlijnck, D., Horváth, I., Johnston, S. L., Kanniess, F., Papadopoulos, N., Papi, A., Russell, R. J., Ryan, D., Samitas, K., ... Gaga, M. (2019). ERS/EAAACI statement on severe exacerbations in asthma in adults: Facts, priorities and key research questions. *European Respiratory Journal*, 54(3), 1900900. <https://doi.org/10.1183/13993003.00900-2019>
- Dvorin, E. L., & Ebell, M. H. (2020, January 15). Short-term systemic corticosteroids: Appropriate use in primary care. *American Family Physician*. <https://www.aafp.org/pubs/afp/issues/2020/0115/p89.html>
- Bourdin, A., Suehs, C., & Charriot, J. (2020). Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship. *European Respiratory Journal*, 55(1), 1902193. <https://doi.org/10.1183/13993003.02193-2019>
- Price, D. B., Trudo, F., Voorham, J., Xu, X., Kerkhof, M., Ling Zhi Jie, J., & Tran, T. N. (2018). Adverse outcomes from initiation of systemic corticosteroids for asthma: Long-term observational study. *Journal of Asthma and Allergy*, Volume 11, 193–204. <https://doi.org/10.2147/jaa.s176026>
- Ekström, M., Nwaru, B. I., Hasvold, P., Wiklund, F., Telg, G., & Janson, C. (2019). Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden. *Allergy*, 74(11), 2181–2190. <https://doi.org/10.1111/all.13874>
- Price, D., Castro, M., Bourdin, A., Fucile, S., & Altman, P. (2020). Short-course systemic corticosteroids in asthma: Striking the balance between efficacy and safety. *European Respiratory Review*, 29(155), 190151. <https://doi.org/10.1183/16000617.0151-2019>
- O’Byrne, P., Fabbri, L. M., Pavord, I. D., Papi, A., Petruzzelli, S., & Lange, P. (2019). Asthma progression and mortality: The role of inhaled corticosteroids. *European Respiratory Journal*, 54(1), 1900491. <https://doi.org/10.1183/13993003.00491-2019>
- Matera, M. G., Rinaldi, B., Calzetta, L., Rogliani, P., & Cazzola, M. (2019). Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. *Pulmonary Pharmacology & Therapeutics*, 58, 101828. <https://doi.org/10.1016/j.pupt.2019.101828>
- Beasley, R., Harper, J., Bird, G., Majiers, I., Weatherall, M., & Pavord, I. D. (2019). Inhaled corticosteroid therapy in adult asthma. time for a new therapeutic dose terminology. *American Journal of Respiratory and Critical Care Medicine*, 199(12), 1471–1477. <https://doi.org/10.1164/rccm.201810-1868ci>
- Murphy, K. R., Hong, J. G., Wandalsen, G., Larenas-Linnemann, D., El Belediy, A., Zaytseva, O. V., & Pedersen, S. E. (2020). Nebulized inhaled corticosteroids in asthma treatment in children 5 years or younger: A systematic review and global expert analysis. *The Journal of Allergy and Clinical Immunology: In Practice*, 8(6), 1815–1827. <https://doi.org/10.1016/j.jaip.2020.01.042>
- Heffler, E., Madeira, L. N., Ferrando, M., Puggioni, F., Racca, F., Malvezzi, L., Passalacqua, G., & Canonica, G. W. (2018). Inhaled corticosteroids safety and adverse effects in patients with asthma. *The Journal of Allergy and Clinical Immunology: In Practice*, 6(3), 776–781. <https://doi.org/10.1016/j.jaip.2018.01.025>
- Thomas EJ. (2021). *TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH*, 9(3). <https://doi.org/10.21522/tijph.2013.09.03>
- Abubaker, J., Zaina, F., Siddiqui, S., Zahid, M., Ullah, S. Z., Abubaker, Z. J., ... & Ullah, S. (2019). Single intramuscular methylprednisolone dose in asthma and chronic obstructive pulmonary disease patients on discharge. *J Pak Med Assoc*, 69(7), 991-994.
- Alangari, A. (2018). Corticosteroids in the treatment of acute asthma. *Annals of Thoracic Medicine*, 9(4), 187. <https://doi.org/10.4103/1817-1737.140120>